

Resolutions of the Board of Directors

- **Proposed dividend matches last year's level**
- **Oscar-Werner Reif suggested to join the Board of Directors**

Aubagne | Goettingen, March 5, 2009 – At today's meeting, the Board of Directors of Sartorius Stedim Biotech S.A. resolved to submit a proposal to the Annual General Shareholders' Meeting (AGM) on April 21, 2008, for payment of a dividend of €0.30 per share for fiscal 2008. The basis for this proposal is the earnings per share, excluding non-cash amortization, of €1.02 reported for 2008. For financial 2007, the dividend paid out was also €0.30 per share.

Furthermore, the Board of Directors will suggest at the AGM to appoint Mr. Oscar-Werner Reif as a member of this Board. Oscar Reif, who earned his doctorate degree in chemical engineering and is currently 44 years old, has been with Sartorius since 1995, and has headed the Biotechnology research and development department with global responsibilities since 2005.

Current Image Files:

Sartorius Stedim Biotech:

<http://www.sartorius-stedim.com/media/content/press/support/Bioprocessing.jpg>

Dr. Oscar-Werner Reif:

http://www.sartorius.com/fileadmin/media/press/Dr_Reif.jpg

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the

Sartorius Stedim Biotech S.A.
Z.I. des Paluds
Avenue de Jouques
B.P. 1051
13781 Aubagne - France

www.sartorius-stedim.com

Press Contact:
Petra Kirchhoff
Tel. +49 (0)551.308.1686

rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions" on a daily basis.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros according to its preliminary figures.

Contact:

Petra Kirchhoff, Vice President of Group Communications

Phone: +49 (0)551/ 308-3324

Fax: +49 (0)551/ 308-3410

E-mail: petra.kirchhoff@sartorius.com